Yarrow Bioscience (YARW) Common Equity (2016 - 2026)

Yarrow Bioscience (YARW) has reported Common Equity for 11 consecutive years, with $22.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 43.26% year-over-year to $22.1 million; the trailing twelve-month figure through Jun 2026 stood at $22.1 million (down 43.26% YoY), and the FY2025 full-year result was $27.8 million, down 46.69% from the prior year.
• Common Equity slipped to $22.1 million in Q2 2026 per YARW's latest filing, from $24.6 million in the prior quarter.
• Across five years, Common Equity topped out at $88.7 million in Q4 2023 and bottomed at $11.5 million in Q3 2023.
• Historically, Common Equity has averaged $44.2 million across 5 years, with a median of $40.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 71.29% in 2023, then surged 452.26% in 2024.
• Over 5 years, Common Equity stood at $31.2 million in 2022, then jumped by 184.39% to $88.7 million in 2023, then sank by 41.3% to $52.1 million in 2024, then plunged by 46.69% to $27.8 million in 2025, then slipped by 20.54% to $22.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $22.1 million, $24.6 million, and $27.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.